Know Cancer

forgot password

Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody For Patients With Previously Treated Non-Hodgkin's Lymphoma With More Than 25% Bone Marrow Involvement

Phase 1
18 Years
Open (Enrolling)
Non-Hodgkin's Lymphoma

Thank you

Trial Information

Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody For Patients With Previously Treated Non-Hodgkin's Lymphoma With More Than 25% Bone Marrow Involvement

The primary endpoint is to determine the maximum tolerated dose of Iodine-131 Anti B-1
Antibody in patients with previously treated NHL having more than 25% bone marrow
involvement with lymphoma. Secondary endpoints include assessment of response rate,
duration of response, relapse-free survival, time to treatment failure, safety, and

The dose escalation will be started at 45cGy and will be escalated in 10cGy increments until
the maximum tolerated dose in reached.

Inclusion Criteria:

- Patients must have a histologically confirmed initial diagnosis of low-grade
non-Hodgkin's B-cell lymphoma according to International Working Formulation (i.e.,
small lymphocytic [with or without plasmacytoid differentiation]; follicular small
cleaved, or follicular, mixed small cleaved and large cell), or low-grade lymphoma
that has transformed to a higher grade histology, or de novo follicular large cell

- Patients must have Ann Arbor Stage IV disease and greater than an average of 25% of
the intratrabecular marrow space involved by NHL in bilateral bone marrow biopsy
specimens as assessed microscopically at study entry. A unilateral bone marrow
biopsy demonstrating greater than 50% involvement with NHL is also adequate for study

- Patients must have been previously treated with chemotherapy and progressed on,
failed to achieve an objective response on, or progressed after completion of their
last chemotherapy.

- Patients must have evidence that their tumor tissue expresses the CD20 antigen.

- Patients must have a performance status of at least 60% on the Karnofsky Performance
Scale and an anticipated survival of at least 3 months.

- Patients must have an ANC greater than 1500 cells/mm3 and a platelet count greater
than or equal to 150,000 cells/mm3 within 14 days of study entry. These blood counts
must be sustained without support of hematopoietic cytokines or transfusion of blood

- Patients must have adequate renal function (defined as serum creatinine less than 1.5
times the upper limit of normal) and hepatic function (defined as total bilirubin
less than 1.5 times the upper limit of normal and AST less than 5 times the upper
limit of normal) within 14 days of study entry.

- Patients must have bi-dimensionally measurable disease. At least one lesion must be
greater than or equal to 2 x 2 cm.

Exclusion Criteria:

- Patients with active obstructive hydronephrosis.

- Patients with New York Heart Association class III or IV heart disease or other
serious illness that would preclude evaluation.

- Patients with prior malignancy other than lymphoma, except for adequately treated
skin cancer, in situ cervical cancer, or other cancer for which the patient has been
disease-free for 5 years. Patients who have been disease-free of another cancer for
greater than 5 years must be carefully assessed at the time of study entry to rule
out recurrent disease.

- Patients with known HIV infection.

- Patients who are HAMA positive.

- Patients with known brain or leptomeningeal metastases.

- Patients who have undergone therapy with either stem cell or bone marrow transplant.

- Patients who have received cytotoxic chemotherapy, immunosuppressants, or cytokine
therapy within 4 weeks prior to study entry (6 weeks for nitrosourea compounds). The
use of systemic steroids must be discontinued at least 1 week prior to study entry.

- Patients who are pregnant or breastfeeding. Patients of childbearing potential must
undergo a serum pregnancy test within 7 days prior to study entry. Males and females
must agree to use effective contraception for 6 months following the
radioimmunotherapy dose.

- Patients with progressive disease within 1 year of irradiation arising in a field
that has been previously irradiated with more than 3500 cGy.

- Patients who are concurrently receiving either approved or non-approved (through
another protocol) anti-cancer drugs or biologics.

- Patients with active infection requiring IV anti-infectives at the time of study

- Patients who have previously received radioimmunotherapy.

- Patients with de novo intermediate- or high-grade NHL, except for intermediate
subtype of follicular large cell NHL.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


United States: Food and Drug Administration

Study ID:




Start Date:

May 1999

Completion Date:

Related Keywords:

  • Non-Hodgkin's Lymphoma
  • Non-Hodgkin's Lymphoma
  • Radioimmunotherapy
  • Monoclonal Antibody
  • Corixa
  • Bexxar
  • Anti-B1 Antibody
  • Tositumomab
  • Iodine -131 Anti-B1 Antibody
  • Iodine I 131 Tositumomab
  • Lymphoma
  • Lymphoma, Non-Hodgkin



Cornell Medical Center New York, New York  10021